Organogenesis Holdings IncNASDAQ:ORGO
- LAST PRICE3.9200
- TODAY'S CHANGE (%)-0.1200 (-2.9703%)
- Bid / Lots3.9100/ 11
- Ask / Lots3.9200/ 2
- Open / Previous Close4.0000 / 4.0400
- Day Range
- 52 Week Range
- Volume142,808
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORGO |
|---|---|---|
| 09:32 ET | 3500 | 4 |
| 09:35 ET | 309 | 4 |
| 09:37 ET | 212 | 4 |
| 09:42 ET | 100 | 3.98 |
| 09:44 ET | 1600 | 3.98 |
| 09:46 ET | 1250 | 3.98 |
| 09:48 ET | 1438 | 4 |
| 09:50 ET | 525 | 3.995 |
| 09:51 ET | 100 | 3.99 |
| 09:53 ET | 100 | 3.99 |
| 09:55 ET | 1986 | 4 |
| 09:57 ET | 1609 | 3.995 |
| 10:00 ET | 3408 | 3.97 |
| 10:02 ET | 700 | 3.97 |
| 10:04 ET | 2372 | 3.97 |
| 10:06 ET | 200 | 3.96 |
| 10:08 ET | 300 | 3.965 |
| 10:09 ET | 300 | 3.965 |
| 10:11 ET | 500 | 3.96 |
| 10:13 ET | 400 | 3.935 |
| 10:15 ET | 500 | 3.945 |
| 10:18 ET | 1560 | 3.935 |
| 10:20 ET | 442 | 3.935 |
| 10:22 ET | 2600 | 3.93 |
| 10:24 ET | 300 | 3.93 |
| 10:26 ET | 663 | 3.92 |
| 10:27 ET | 100 | 3.92 |
| 10:29 ET | 228 | 3.92 |
| 10:31 ET | 2170 | 3.92 |
| 10:33 ET | 200 | 3.915 |
| 10:36 ET | 100 | 3.915 |
| 10:38 ET | 1100 | 3.91 |
| 10:40 ET | 1900 | 3.915 |
| 10:42 ET | 6146 | 3.885 |
| 10:44 ET | 600 | 3.885 |
| 10:45 ET | 3298 | 3.87 |
| 10:47 ET | 900 | 3.88 |
| 10:54 ET | 600 | 3.88 |
| 10:56 ET | 700 | 3.87 |
| 10:58 ET | 800 | 3.88 |
| 11:00 ET | 300 | 3.88 |
| 11:02 ET | 500 | 3.88 |
| 11:03 ET | 2700 | 3.895 |
| 11:05 ET | 800 | 3.9 |
| 11:07 ET | 100 | 3.89 |
| 11:09 ET | 900 | 3.89 |
| 11:12 ET | 100 | 3.89 |
| 11:14 ET | 4001 | 3.885 |
| 11:16 ET | 500 | 3.895 |
| 11:18 ET | 500 | 3.895 |
| 11:20 ET | 400 | 3.905 |
| 11:21 ET | 200 | 3.91 |
| 11:23 ET | 100 | 3.925 |
| 11:25 ET | 3086 | 3.91 |
| 11:27 ET | 705 | 3.91 |
| 11:32 ET | 100 | 3.915 |
| 11:34 ET | 1667 | 3.905 |
| 11:36 ET | 700 | 3.905 |
| 11:38 ET | 14054 | 3.95 |
| 11:39 ET | 13958 | 3.96 |
| 11:41 ET | 1000 | 3.95 |
| 11:43 ET | 480 | 3.94 |
| 11:45 ET | 9773 | 3.93 |
| 11:48 ET | 900 | 3.945 |
| 11:52 ET | 500 | 3.95 |
| 11:54 ET | 200 | 3.94 |
| 11:56 ET | 3872 | 3.93 |
| 11:57 ET | 600 | 3.93 |
| 11:59 ET | 1100 | 3.92 |
| 12:01 ET | 1025 | 3.91 |
| 12:03 ET | 100 | 3.92 |
| 12:06 ET | 2600 | 3.915 |
| 12:08 ET | 2646 | 3.92 |
Nov 22, 2024
Organogenesis Expands Manufacturing Capacity to Support Future Growth, from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones
4:05PM ET on Friday Nov 22, 2024 by Dow Jones
Nov 15, 2024
Press Release: Organogenesis Commends Final LCDs, from 9:25AM ET on Friday Nov 15, 2024 by Dow Jones
9:25AM ET on Friday Nov 15, 2024 by Dow JonesOrganogenesis Commends Final LCDs, from 9:25AM ET on Friday Nov 15, 2024 by Dow Jones
9:25AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 12, 2024
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Organogenesis Holdings 3Q EPS 9c >ORGO, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Organogenesis Holdings Inc | 536.9M | -69.1x | --- |
Ironwood Pharmaceuticals Inc | 550.5M | -221.3x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Amylyx Pharmaceuticals Inc | 361.2M | -1.4x | --- |
Amarin Corporation PLC | 225.7M | -5.3x | --- |
Ginkgo Bioworks Holdings Inc | 391.2M | -0.6x | --- |
Company Information
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.
Contact Information
- Headquarters
- 85 Dan RdCANTON, MA, United States 02021-2810
- Phone
- 781-575-0775
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gary Gillheeney
- Chief Financial Officer
- David Francisco
- Chief Operating Officer
- Patrick Bilbo
- Chief Administrative and Legal Officer
- Lori Freedman
- Vice President - Health Policy
- Antonio Montecalvo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $536.9M |
|---|---|
Revenue (TTM) | $455.0M |
Shares Outstanding | 132.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.73 |
EPS | $-0.06 |
Book Value | $2.12 |
P/E Ratio | -69.1x |
Price/Sales (TTM) | 1.2 |
Price/Cash Flow (TTM) | 57.1x |
Operating Margin | -2.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
